Press Releases and Events
PRESS RELEASES
Press Release | December 16, 2024
Press Release | December 10, 2024
Crinetics Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | December 9, 2024
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
READ MORE
Press Release | November 15, 2024
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
READ MORE
Press Release | November 12, 2024
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
READ MORE
Press Release | November 12, 2024
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
READ MORE
Press Release | November 11, 2024
Crinetics Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | October 10, 2024
Crinetics Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | October 8, 2024
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
READ MORE
Press Release | October 8, 2024
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
